Drugs in autoimmune diseases

Area of Science:

• Immunology
• Pharmacology

Background:

• Autoimmune diseases result from a loss of self-tolerance, leading to tissue damage.
• The pathogenesis involves complex immunologic, viral, hormonal, and genetic factors.
• Current treatments like cytostatics and corticosteroids have significant side effects and limitations.

Purpose of the Study:

• To review the mechanisms of autoimmunity and the current landscape of immunosuppressive therapies.
• To highlight the limitations of existing treatments for autoimmune disorders.
• To discuss emerging and future directions in the development of novel immunosuppressive drugs.

Main Methods:

• Review of existing literature on autoimmunity and immunosuppression.
• Analysis of the mechanisms of action and side effects of current therapies.
• Discussion of novel therapeutic agents and future research directions.

Main Results:

• Autoimmunity involves complex immunological networks and diverse contributing factors.
• Non-specific immunosuppressants (cytostatics) and corticosteroids have severe side effects and limited long-term efficacy.
• Cyclosporin A and monoclonal antibodies represent more targeted approaches.
• New agents like Ciamexone and Leflunomide show promise.

Conclusions:

• There is a critical need for more specific, orally active, and well-tolerated immunosuppressive drugs.
• Future drug development should focus on low molecular weight, chemically defined compounds.
• Advancements in immunopharmacology aim to improve long-term management of autoimmune diseases.